TCM
CRDF icon

Tekla Capital Management’s Cardiff Oncology CRDF Stock Holding History

Tekla Capital Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-7,639
Closed -$3.13M – 142
2015
Q3 		$3.13M Buy
+7,639
New +$4M 0.11% 126
2015
Q2 		– Sell
-9,028
Closed -$4.43M – 123
2015
Q1 		$4.43M Buy
+9,028
New +$3.85M 0.18% 87

Other funds holding CRDF

BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MWVC
Morgens Waterfall Vintiadis & Co New York $131M AUM 101.21% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Tekla Capital Management's CRDF Position: Q4 2015 in Review

Tekla Capital Management sold out of Cardiff Oncology (CRDF) in Q4 2015, closing a stake of 7,639 shares — an estimated $3.13M sold.

Tekla Capital Management first reported a position in CRDF in Q1 2015 and held it in 2 quarters. The position peaked at $4.43M in Q1 2015. 66 funds tracked by Wall St. Rank hold CRDF as of Q4 2015.

  • Tekla Capital Management reported no remaining Cardiff Oncology position as of Q4 2015 after selling out during the quarter.
  • Tekla Capital Management sold 7,639 Cardiff Oncology shares in Q4 2015, an estimated $3.13M.
  • Tekla Capital Management first reported a position in Cardiff Oncology in Q1 2015 and held it in 2 quarters.
  • Tekla Capital Management's Cardiff Oncology position peaked at $4.43M in Q1 2015.
  • 66 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2015.

Based on Tekla Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.